Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Pfizer will Co-promote Takeda Diabetes Drug

publication date: Dec 15, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer has taken on the job of co-promoting a diabetes drug in China for Takeda Pharmaceutical Company. Actos® (pioglitazone HCl), an oral treatment for diabetes 2, produces over $4 billion of annual revenues for Takeda worldwide. The agreement will be in force until 2020 and pays Pfizer a fixed percentage of sales revenue. More details...

Stock Symbol: (NYSE: PFE)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners